Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul 4;7(1):14.
doi: 10.1186/s13167-016-0063-5. eCollection 2016.

Current status of biomarker research in neurology

Jiri Polivka  1 , Jiri Polivka Jr  2 , Kristyna Krakorova  1 , Marek Peterka  1 , Ondrej Topolcan  3
Affiliations
Review

Current status of biomarker research in neurology

Jiri Polivka et al. EPMA J. .

Abstract

Neurology is one of the typical disciplines where personalized medicine has been recently becoming an important part of clinical practice. In this article, the brief overview and a number of examples of the use of biomarkers and personalized medicine in neurology are described. The various issues in neurology are described in relation to the personalized medicine and diagnostic, prognostic as well as predictive blood and cerebrospinal fluid biomarkers. Such neurological domains discussed in this work are neuro-oncology and primary brain tumors glioblastoma and oligodendroglioma, cerebrovascular diseases focusing on stroke, neurodegenerative disorders especially Alzheimer's and Parkinson's diseases and demyelinating diseases such as multiple sclerosis. Actual state of the art and future perspectives in diagnostics and personalized treatment in diverse domains of neurology are given.

Keywords: Alzheimer’s disease; Biomarker; Multiple sclerosis; Neuro-oncology; Parkinson’s disease; Personalized medicine; Predictive preventive personalized medicine; Stroke.

PubMed Disclaimer

References

    1. Gottlieb S. Personalised medicine comes a step closer for asthma. BMJ. 2000;321:724. doi: 10.1136/bmj.321.7263.724. - DOI - PMC - PubMed
    1. Nebert DW, Zhang G, Vesell ES. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons. Future Directions Drug Metab Rev. 2008;40:187–224. doi: 10.1080/03602530801952864. - DOI - PMC - PubMed
    1. Golubnitschaja O, Costigliola V, EPMA General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 2012;3:14. doi: 10.1186/1878-5085-3-14. - DOI - PMC - PubMed
    1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109. doi: 10.1007/s00401-007-0243-4. - DOI - PMC - PubMed
    1. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110. doi: 10.1016/j.ccr.2009.12.020. - DOI - PMC - PubMed

LinkOut - more resources